{"id":5610,"date":"2026-08-19T09:49:50","date_gmt":"2026-08-19T13:49:50","guid":{"rendered":"https:\/\/humanbodycalculator.com\/blogs\/?p=5610"},"modified":"2026-11-14T07:37:43","modified_gmt":"2026-11-14T12:37:43","slug":"moderna-melanoma-vaccine","status":"publish","type":"post","link":"https:\/\/humanbodycalculator.com\/blogs\/moderna-melanoma-vaccine\/","title":{"rendered":"Personalized mRNA Melanoma Vaccines &amp; Metastasis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Personalized mRNA cancer vaccines \u2014 led by Moderna and Merck&#8217;s intismeran autogene (mRNA-4157\/V940) \u2014 are investigational immunotherapies custom-built from a patient&#8217;s own tumor DNA to train the immune system to hunt down and destroy microscopic cancer cells before they spread.<\/strong> Following landmark Phase 3 data presented at the 2026 European Society for Medical Oncology (ESMO) Congress \u2014 alongside early international reports from programs like Russia&#8217;s NeoOncovac \u2014 individualized mRNA vaccines are rapidly reshaping how doctors prevent melanoma metastasis. Here is how the technology works inside the body, what the latest clinical trial numbers show, and what patients should know about benefits, risks, and availability.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Key Takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic, not preventive.<\/strong> Personalized mRNA melanoma vaccines treat patients who have already had melanoma surgically removed \u2014 they do not prevent skin cancer in healthy people.<\/li>\n\n\n\n<li><strong>Proven Phase 3 reduction in recurrence and metastasis.<\/strong> In the 1,157-patient Phase 3 INTerpath-001 trial reported in late 2026, intismeran autogene plus Keytruda cut the risk of melanoma recurrence or death by 42% and lowered the risk of distant metastasis or death by 38% compared with Keytruda alone.<\/li>\n\n\n\n<li><strong>Global research is accelerating.<\/strong> Alongside Moderna and Merck&#8217;s late-stage program, international candidates \u2014 including Russia&#8217;s NeoOncovac and BioNTech&#8217;s neoantigen vaccines \u2014 are testing similar personalized mRNA approaches against metastatic tumors.<\/li>\n\n\n\n<li><strong>Not yet FDA-approved.<\/strong> Intismeran autogene remains investigational; Merck and Moderna are preparing regulatory submissions following their Phase 3 readout.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Personalized mRNA Cancer Vaccines: The 2026 Melanoma Breakthrough\" width=\"1200\" height=\"675\" src=\"https:\/\/www.youtube.com\/embed\/G7BieBPhMZs?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">What Is a Personalized mRNA Cancer Vaccine?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The lead U.S. candidate, developed jointly by <a href=\"https:\/\/www.modernatx.com\/en-US\" target=\"_blank\" rel=\"noopener\">Moderna<\/a> and <a href=\"https:\/\/www.merck.com\/research\/oncology\/\" target=\"_blank\" rel=\"noopener\">Merck<\/a>, goes by several names across medical journals and news reports:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>mRNA-4157<\/strong> \u2014 Moderna&#8217;s original laboratory and research code<\/li>\n\n\n\n<li><strong>V940<\/strong> \u2014 Merck&#8217;s internal clinical development code<\/li>\n\n\n\n<li><strong>Intismeran autogene<\/strong> \u2014 the official generic (INN) drug name<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">All three refer to the exact same therapy. Medically classified as an <strong>individualized neoantigen therapy (INT)<\/strong>, it differs fundamentally from a flu shot or COVID-19 vaccine. Rather than being mass-produced in a factory to prevent viral infection, this therapeutic melanoma treatment is custom-manufactured for each patient using genetic sequencing from their own surgically removed tumor, then administered alongside Keytruda (pembrolizumab), Merck&#8217;s anti-PD-1 immunotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Latest Clinical Trial Results: Phase 3 INTerpath-001 Data<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">After announcing positive topline results in August 2026, Merck and Moderna unveiled the full late-breaking dataset from the Phase 3 <strong>INTerpath-001<\/strong> trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05933577\" target=\"_blank\" rel=\"noopener\">NCT05933577<\/a>) at the ESMO 2026 Presidential Symposium, with simultaneous acceptance in <em>The New England Journal of Medicine<\/em>. It marks the first time an individualized mRNA cancer therapy has demonstrated statistically significant, clinically meaningful success in a large, randomized Phase 3 trial.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The global study enrolled 1,157 patients with completely resected, high-risk (stage IIB\u2013IV) melanoma, randomly assigning them 2:1 to receive intismeran autogene plus Keytruda versus Keytruda plus placebo. Key findings include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>42% lower risk of recurrence or death<\/strong> (recurrence-free survival) compared with Keytruda alone.<\/li>\n\n\n\n<li><strong>38% lower risk of distant metastasis or death<\/strong> (distant metastasis-free survival), demonstrating strong protection against cancer spreading to distant organs.<\/li>\n\n\n\n<li><strong>82% of patients remained recurrence-free at two years<\/strong> on the combination therapy, compared with 70% receiving Keytruda alone.<\/li>\n\n\n\n<li><strong>Consistent safety profile,<\/strong> with no new safety signals emerging in the larger Phase 3 patient group.<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">&#8220;Today&#8217;s results represent a landmark moment for adjuvant melanoma treatment&#8230; [Intismeran] has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer.&#8221;<\/p>\n<cite>\u2014 Professor Georgina Long, principal investigator of INTerpath-001 and Medical Director, Melanoma Institute Australia (<a href=\"https:\/\/www.merck.com\/news\/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium\/\" target=\"_blank\" rel=\"noopener\">source<\/a>)<\/cite><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\">How Personalized mRNA Vaccines Target Metastasis<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Conventional chemotherapy and radiation attack rapidly dividing cells broadly. By contrast, a personalized mRNA cancer vaccine acts like a biological &#8220;wanted poster,&#8221; training the body&#8217;s own T-cells to recognize and eliminate microscopic melanoma cells hiding elsewhere in the body before they can form new metastatic tumors. Here is how the process works step by step:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Tumor DNA sequencing.<\/strong> After a surgeon removes the patient&#8217;s melanoma tumor, a tissue sample undergoes next-generation genetic sequencing to map its unique mutations.<\/li>\n\n\n\n<li><strong>Neoantigen selection.<\/strong> Bioinformatic algorithms analyze those mutations and select up to <strong>34 neoantigens<\/strong> \u2014 abnormal protein markers present exclusively on that patient&#8217;s cancer cells, not on healthy tissue.<\/li>\n\n\n\n<li><strong>Custom mRNA synthesis.<\/strong> A synthetic mRNA strand encoding all 34 neoantigens is manufactured specifically for that individual patient.<\/li>\n\n\n\n<li><strong>Lipid nanoparticle delivery.<\/strong> The custom mRNA is encapsulated in protective lipid nanoparticles and injected into the muscle.<\/li>\n\n\n\n<li><strong>T-cell activation.<\/strong> Healthy cells read the mRNA instructions and display the harmless neoantigen proteins on their surface, alerting cytotoxic T-cells to hunt down any remaining cancer cells carrying those exact markers.<\/li>\n\n\n\n<li><strong>Checkpoint blockade synergy.<\/strong> Keytruda is given alongside the vaccine to block the PD-1 pathway that tumors use to shut down immune attacks \u2014 keeping the newly trained T-cells active against metastatic spread.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">In clinical protocols, patients receive the mRNA vaccine roughly once every three weeks for up to nine doses, paired with Keytruda infusions every six weeks over approximately one year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Long-Term Benefits: Phase 2b vs. Phase 3 Data<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The clinical case for intismeran autogene is backed by both five-year follow-up data from the Phase 2b <strong>KEYNOTE-942<\/strong> trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03897881\" target=\"_blank\" rel=\"noopener\">NCT03897881<\/a>) and the larger Phase 3 <strong>INTerpath-001<\/strong> confirmation:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Clinical Trial &amp; Follow-Up<\/th><th>Reduced Risk of Recurrence\/Death (RFS)<\/th><th>Reduced Risk of Distant Metastasis (DMFS)<\/th><\/tr><\/thead><tbody><tr><td>Phase 2b KEYNOTE-942 (~2 years)<\/td><td>44%<\/td><td>65%<\/td><\/tr><tr><td>Phase 2b KEYNOTE-942 (3 years)<\/td><td>49%<\/td><td>62%<\/td><\/tr><tr><td>Phase 2b KEYNOTE-942 (5 years)<\/td><td>49%<\/td><td>59%<\/td><\/tr><tr><td>Phase 3 INTerpath-001 (ESMO 2026)<\/td><td>42%<\/td><td>38%<\/td><\/tr><\/tbody><\/table><figcaption class=\"wp-element-caption\">Data sources: Merck\/Moderna 5-year KEYNOTE-942 update and ESMO 2026 Phase 3 INTerpath-001 presentation.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Why Preventing Metastasis Matters for Melanoma Patients<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Melanoma becomes dramatically harder to treat once it metastasizes to distant organs such as the lungs, liver, or brain. According to <a href=\"https:\/\/www.merck.com\/news\/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium\/\" target=\"_blank\" rel=\"noopener\">American Cancer Society estimates cited by Merck<\/a>, roughly 112,000 new melanoma cases and more than 8,500 deaths occur in the U.S. annually. Most relapses happen within the first two years after surgery, and the majority are metastatic rather than local \u2014 making the post-surgical window the most critical time to eliminate circulating tumor cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Global mRNA Cancer Vaccines: NeoOncovac, BioNTech &amp; Other Trials<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While Moderna and Merck&#8217;s intismeran autogene leads global clinical testing with mature Phase 3 data, several other research teams worldwide are advancing personalized mRNA vaccines against melanoma and metastatic cancers:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NeoOncovac (Russia):<\/strong> Developed jointly by Moscow&#8217;s Gamaleya National Research Center and the Blokhin Oncology Center, NeoOncovac uses a similar personalized mRNA approach tailored to a patient&#8217;s tumor mutations. In November 2026, Gamaleya scientific director Alexander Gintsburg reported that the first melanoma patient treated with NeoOncovac achieved complete remission with no detectable metastases after four months, noting that six patients had received doses with plans to treat 20 by year-end. However, unlike Moderna&#8217;s 1,157-patient Phase 3 trial, NeoOncovac remains in very early, small-scale human testing without published peer-reviewed randomized trial results, and treated patients require multi-year follow-up to confirm durability.<\/li>\n\n\n\n<li><strong>BioNTech &amp; Genentech (Autogene Cevumeran):<\/strong> In parallel U.S. and European trials, BioNTech and Genentech are testing individualized mRNA neoantigen vaccines in melanoma, pancreatic cancer, and colorectal cancer, showing durable multi-year T-cell responses in early studies.<\/li>\n\n\n\n<li><strong>Expanding INTerpath Trials:<\/strong> Merck and Moderna are also running Phase 2 and Phase 3 studies evaluating intismeran autogene across non-small cell lung cancer, bladder cancer, and renal cell carcinoma.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Moderna Melanoma Vaccine Side Effects &amp; Risks<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Because intismeran autogene is administered alongside Keytruda, patients experience side effects associated with both therapies. Clinical data compiled by <a href=\"https:\/\/www.targetedonc.com\/view\/mrna-4157-plus-pembrolizumab-continues-to-improve-rfs-in-high-risk-melanoma\" target=\"_blank\" rel=\"noopener\">Targeted Oncology<\/a> highlights the most frequent reactions linked directly to the mRNA vaccine component:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Side Effect<\/th><th>Reported Frequency<\/th><\/tr><\/thead><tbody><tr><td>Fatigue<\/td><td>~61%<\/td><\/tr><tr><td>Injection site pain<\/td><td>~56\u201357%<\/td><\/tr><tr><td>Chills<\/td><td>~49\u201350%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">These reactions are typically mild to moderate and resolve within a few days \u2014 comparable to a standard mRNA COVID-19 shot, though experienced across multiple scheduled doses. Crucially, adding the personalized vaccine did <strong>not<\/strong> substantially increase severe toxicity: grade 3 or higher treatment-related adverse events occurred in roughly 25% of patients receiving the combination versus 20% receiving Keytruda alone, and the vaccine did not amplify immune-related side effects.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Immune-Related Risks From Keytruda<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Because pembrolizumab removes natural checkpoints on the immune system, it carries an established risk of <strong>immune-mediated adverse reactions<\/strong>, where activated immune cells inflame healthy tissues. These can involve the lungs (pneumonitis), colon (colitis), liver (hepatitis), hormone glands (thyroid, pituitary, adrenal), kidneys, or skin. Full safety information is detailed in Merck&#8217;s <a href=\"https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" target=\"_blank\" rel=\"noopener\">official KEYTRUDA prescribing information<\/a>. Oncologists monitor patients closely through routine lab tests so any inflammation can be treated promptly with corticosteroids.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Is the Moderna Melanoma Vaccine FDA-Approved?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Not yet.<\/strong> Intismeran autogene (mRNA-4157\/V940) remains an investigational therapy and is not commercially available outside clinical trials. Its regulatory path to date includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>February 2023<\/strong> \u2014 FDA grants <a href=\"https:\/\/www.onclive.com\/view\/fda-grants-breakthrough-therapy-designation-to-mrna-4157-v940-plus-pembrolizumab-in-high-risk-melanoma\" target=\"_blank\" rel=\"noopener\">Breakthrough Therapy Designation<\/a> to accelerate development and regulatory review.<\/li>\n\n\n\n<li><strong>July 2023<\/strong> \u2014 Phase 3 INTerpath-001 trial launches enrollment across global oncology centers.<\/li>\n\n\n\n<li><strong>August 2026<\/strong> \u2014 Phase 3 trial meets its primary recurrence-free survival and secondary distant metastasis-free survival endpoints.<\/li>\n\n\n\n<li><strong>October\u2013November 2026<\/strong> \u2014 Full Phase 3 results are presented at ESMO 2026, accepted by <em>The New England Journal of Medicine<\/em>, and highlighted at Moderna&#8217;s Analyst Day as the companies prepare formal global regulatory filings.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">With Breakthrough Therapy status and positive Phase 3 data in hand, Merck and Moderna are moving toward formal FDA Biologics License Application (BLA) discussions. Until regulatory approval is granted, access remains restricted to eligible clinical trial participants.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Who Might Be Eligible?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In completed and ongoing adjuvant melanoma studies, eligibility has focused on adults with <strong>completely resected, high-risk cutaneous melanoma<\/strong> (stages IIB, IIC, III, or IV) who have undergone full surgical tumor removal and have not previously received systemic therapy. Because manufacturing requires sequencing actual tumor tissue, patients must have sufficient viable tumor sample preserved from surgery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Personalized mRNA Cancer Vaccine vs. Traditional Vaccine<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th>Feature<\/th><th>Traditional Vaccine (e.g., Flu, COVID-19)<\/th><th>Personalized mRNA Cancer Vaccine (mRNA-4157)<\/th><\/tr><\/thead><tbody><tr><td>Primary Goal<\/td><td>Prevent viral infection in healthy individuals<\/td><td>Prevent cancer relapse and metastasis after surgery<\/td><\/tr><tr><td>Target Population<\/td><td>General public<\/td><td>Diagnosed cancer patients post-tumor resection<\/td><\/tr><tr><td>Manufacturing<\/td><td>Mass-produced identical batches<\/td><td>Custom-sequenced from each patient&#8217;s tumor DNA<\/td><\/tr><tr><td>Combination Therapy<\/td><td>Given alone<\/td><td>Paired with checkpoint immunotherapy (Keytruda)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Can a personalized mRNA cancer vaccine stop existing metastasis?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In Moderna and Merck&#8217;s Phase 3 trial, the vaccine was given after surgery to prevent microscopic cancer cells from spreading into distant metastases \u2014 reducing that risk by 38% compared with Keytruda alone. Early international studies, such as Russia&#8217;s NeoOncovac, are also exploring personalized mRNA vaccines in patients with active metastatic melanoma, though larger controlled trials are needed to confirm those early case reports.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is the Moderna melanoma vaccine the same as the COVID-19 vaccine?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Both rely on mRNA and lipid nanoparticle delivery, but they carry completely different genetic instructions. The COVID-19 vaccine teaches the immune system to recognize a viral spike protein, whereas intismeran autogene encodes up to 34 unique mutations found only in an individual patient&#8217;s tumor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How is the melanoma mRNA vaccine administered?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">It is given as an intramuscular injection roughly every three weeks for up to nine doses, alongside intravenous Keytruda infusions every six weeks, over a treatment course lasting about one year.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What are the most common side effects of the mRNA melanoma vaccine?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Fatigue (~61%), injection-site pain (~56\u201357%), and chills (~49\u201350%) are the most commonly reported reactions attributed to the vaccine component. These symptoms are generally mild to moderate and temporary.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">When will the Moderna melanoma vaccine be available to patients?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">There is no official FDA approval date yet. Following the full Phase 3 data presentation at ESMO 2026, Merck and Moderna are preparing regulatory submissions. Until FDA approval is granted, patients can only access the therapy by enrolling in an active clinical trial.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does insurance cover personalized mRNA cancer vaccines?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Because intismeran autogene is not yet FDA-approved, it is not covered by commercial insurance or Medicare as a standard prescription. In clinical trials, the investigational vaccine is provided at no cost to participants, though routine care costs are billed normally.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>Also Read:<\/strong> <a href=\"https:\/\/humanbodycalculator.com\/blogs\/focal-therapy-for-prostate-cancer-benefits-risks-candidacy\/\">Focal Therapy for Prostate Cancer: Benefits, Risks &amp; Candidacy<\/a><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Medical Disclaimer:<\/strong> This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Intismeran autogene (mRNA-4157\/V940) and NeoOncovac are investigational therapies and are not currently approved by the U.S. Food and Drug Administration (FDA). Always consult a licensed oncologist or dermatologist regarding melanoma staging, treatment options, and clinical trial eligibility.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Personalized mRNA cancer vaccines \u2014 led by Moderna and Merck&#8217;s intismeran autogene (mRNA-4157\/V940) \u2014 are investigational immunotherapies custom-built from a &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"Personalized mRNA Melanoma Vaccines &amp; Metastasis\" class=\"read-more button\" href=\"https:\/\/humanbodycalculator.com\/blogs\/moderna-melanoma-vaccine\/#more-5610\" aria-label=\"Read more about Personalized mRNA Melanoma Vaccines &amp; Metastasis\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":5611,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292],"tags":[],"class_list":["post-5610","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-oncology","resize-featured-image"],"_links":{"self":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts\/5610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/comments?post=5610"}],"version-history":[{"count":5,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts\/5610\/revisions"}],"predecessor-version":[{"id":5701,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/posts\/5610\/revisions\/5701"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/media\/5611"}],"wp:attachment":[{"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/media?parent=5610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/categories?post=5610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/humanbodycalculator.com\/blogs\/wp-json\/wp\/v2\/tags?post=5610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}